Autoimmune disorders are considered to be one of the causes of dilated cardiomyopathy (DCM). Immunoglobulin G3 subclass antibodies are suggested to play a role in the pathogenesis of DCM.
Immunoadsorption plasmapheresis (IAPP) is a therapeutic apheresis treatment for DCM.
Because angiotensin converting enzyme inhibitor (ACE-I) drugs are contraindicated when IAPP with Imsorba® is performed, ACE-I therapy should be discontinued or switched to other drugs, such as an angiotensin II receptor blocker, before starting IAPP.
KeywordsDilate Cardiomyopathy Angiotensin Converting Enzyme Inhibitor Adsorption Column Angiotensin Converting Enzyme Inhibitor Therapy Therapeutic Apheresis